254 related articles for article (PubMed ID: 25576920)
21. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
22. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
23. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
[TBL] [Abstract][Full Text] [Related]
24. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Choi YH
Int J Oncol; 2005 Aug; 27(2):473-9. PubMed ID: 16010430
[TBL] [Abstract][Full Text] [Related]
25. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
[TBL] [Abstract][Full Text] [Related]
27. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
[TBL] [Abstract][Full Text] [Related]
28. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
29. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG
Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075
[TBL] [Abstract][Full Text] [Related]
30. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
32. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
33. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
34. Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.
Simmons JK; Michalowski AM; Gamache BJ; DuBois W; Patel J; Zhang K; Gary J; Zhang S; Gaikwad S; Connors D; Watson N; Leon E; Chen JQ; Kuehl WM; Lee MP; Zingone A; Landgren O; Ordentlich P; Huang J; Mock BA
Mol Cancer Ther; 2017 Sep; 16(9):2008-2021. PubMed ID: 28522584
[TBL] [Abstract][Full Text] [Related]
35. Curbing autophagy and histone deacetylases to kill cancer cells.
Gammoh N; Marks PA; Jiang X
Autophagy; 2012 Oct; 8(10):1521-2. PubMed ID: 22894919
[TBL] [Abstract][Full Text] [Related]
36. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
37. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
38. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Shukla S; Rizvi F; Raisuddin S; Kakkar P
Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.
Zhang J; Ng S; Wang J; Zhou J; Tan SH; Yang N; Lin Q; Xia D; Shen HM
Autophagy; 2015 Apr; 11(4):629-42. PubMed ID: 25919885
[TBL] [Abstract][Full Text] [Related]
40. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
